Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Norlin Jenny
fil dr | projektledare

Arbetsområden
Jenny Norlin disputerade vid Umeå universitet i November 2013 med avhandlingen “Effectiveness and costs of new medical technologies: register-based research in psoriasis”.

Jenny arbetar med hälsoekonomiska utvärdering och analyser av medicinsk teknologi och interventioner, främst inom dermatologiska sjukdomar. Forskningsprojekten inkluderar analyser av registerdata från nationella och regionala patientregister samt kvalitetsregister. Andra fokusområden innefattar analyser av olika livskvalitetsmått och QALYs.

Jenny har tidigare erfarenhet som Global Health Economics and Outcomes Research Manager inom läkemedelsindustrin.

Urval av publiceringar

Norlin JM, Calara PS, Persson U & Schmitt-Egenolf M
Real-world outcomes in 2,646 psoriasis patients: One in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy
Journal of Dermatological Treatment, 2017. E-publication ahead of print.

Calara P S, Norlin J M, Althin R, Steen Carlsson K & Schmitt-Egenolf M
Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice
BioDrugs 2016; 30(2): 145-151
Publicerad online: 16 februari 2016


Ragnarson Tennvall G., Norlin J.M., Malmberg I., Erlendsson A.M. & Hædersdal M.
Health related quality of life in patients with actinic keratosis – an observational study of patients treated in dermatology specialist care in Denmark
Health and Quality of Life Outcomes 2015; 13(111): 1-9

Norlin J, Steen Carlsson K, Persson U & Schmitt-Egenolf M
Resource Use in Patients with Psoriasis After the Introduction of Biologics in Sweden
Acta Derm Venereol 2015; 95: 156–161
INVESTIGATIVE REPORT


Norlin JM, Schmitt-Egenolf M, Steen Carlsson K, & Persson U
Registerstudier mäter effektivitet av läkemedel I klinisk praxis. Exemplet PsoReg – omfördelning av systemisk terapi kan ge ökad effektivitet
Läkartidningen, 2014 Jun 11-17; 111(24): 1061-3

Willis M, Erntoft S, Persson S, Norlin J, Persson U
Willingness-to-pay to access Ingenol Mebutate Gel for Actinic Keratosis Treatment in the U.S. Setting
Journal of Health Economics and Outcomes Research 2014; 2(1): 1-14

Norlin J M, Steen Carlsson K, Persson U & Schmitt-Egenolf M
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
Dermatology Published Online First: January 16, 2013

Norlin J M, Steen Carlsson K, Persson U & Schmitt-Egenolf M
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients
British Journal of Dermatology. 2012; 166(4): 797-802

Norlin J, Elf J, Svensson PJ & Steen Carlsson K
A Cost-effectiveness Analysis of Diagnostic Algorithms of Deep Vein Thrombosis at the Emergency Department
Thrombosis Research, 2010; 126: 195-199.

Norlin, J. M. (2013). Effectiveness and costs of new medical technologies : register-based research in psoriasis. Umeå: Umeå universitet. Umeå University medical dissertations.

Norlin, J. M., Carlsson, K. S., Persson, U., & Schmitt-Egenolf, M. (2015). Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden. BioDrugs, 29(6), 389-398. doi:10.1007/s40259-015-0151-4
© IHE 2017